Aberdeen Group’s CytomX Therapeutics CTMX Stock Holding History

Aberdeen Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,403	Closed	-$381K	–	902
2018 Q1	$381K	Buy	+13,403	New	+$383K	﹤0.01%	778

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Aberdeen Group's CTMX Position: Q2 2018 in Review

Aberdeen Group sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 13,403 shares — an estimated $381K sold.

Aberdeen Group first reported a position in CTMX in Q1 2018 and held it in 1 quarter. The position peaked at $381K in Q1 2018. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

Aberdeen Group reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
Aberdeen Group sold 13,403 CytomX Therapeutics shares in Q2 2018, an estimated $381K.
Aberdeen Group first reported a position in CytomX Therapeutics in Q1 2018 and held it in 1 quarter.
Aberdeen Group's CytomX Therapeutics position peaked at $381K in Q1 2018.
142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on Aberdeen Group's 13F filing for Q2 2018, filed 9 Aug 2018.